MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Perlegen Sciences announced today that it has completed the collection of more than 3,000 DNA samples from diabetic patients treated with Actos® and Avandia® in order to analyze the genetic variability associated with adverse events due to treatment with this class of medications.
